Compare CIB & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIB | MEDP |
|---|---|---|
| Founded | 1945 | 1992 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 16.1B |
| IPO Year | 1995 | 2016 |
| Metric | CIB | MEDP |
|---|---|---|
| Price | $76.44 | $541.32 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 12 |
| Target Price | $57.33 | ★ $479.64 |
| AVG Volume (30 Days) | ★ 479.0K | 240.7K |
| Earning Date | 02-19-2026 | 02-09-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | 22.14 | ★ 25.36 |
| EPS | 1.96 | ★ 14.32 |
| Revenue | ★ $6,289,868,892.00 | $2,358,373,000.00 |
| Revenue This Year | $33.27 | $21.43 |
| Revenue Next Year | $7.26 | $11.99 |
| P/E Ratio | ★ $10.34 | $37.80 |
| Revenue Growth | ★ 15.25 | 13.88 |
| 52 Week Low | $35.44 | $250.05 |
| 52 Week High | $86.31 | $628.92 |
| Indicator | CIB | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 34.96 |
| Support Level | $76.18 | $538.29 |
| Resistance Level | $84.24 | $597.88 |
| Average True Range (ATR) | 2.80 | 22.23 |
| MACD | -0.95 | -7.69 |
| Stochastic Oscillator | 11.91 | 8.91 |
Grupo Cibest SA formerly BanColombia SA is a financial services company. A conglomerate of financial institutions, BanColombia offers a wide range of product offerings and financial services, including loans to small and midsize enterprises and governments, leasing, factoring, and asset management. The company's operations are in Colombia, Panama, El Salvador, the United States of America, Puerto Rico, Bermuda, and Guatemala. The Bank has the following segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking and All other segments. The majority of revenue is generated from the Banking Colombia segment.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.